JNJ
A paper gets the red pen treatment
Johnson & Johnson just watched one of its talc-defense talking points get dunked into the editorial trash can. On April 19, The Lancet retracted a 1977 commentary that had been used to support the safety of cosmetic talc after editors found the author was a paid consultant for J&J — and that relationship was never disclosed.
Why this matters more than a dusty footnote
If this feels like ancient history, that’s because it is. But in courtroom land, old papers can still pull a lot of weight. This one had been cited as part of J&J’s argument that its talc products weren’t dangerous, so ripping it out of the record could hand plaintiffs a cleaner lane to argue the company knew more than it let on.
The talc saga keeps dragging on
This comes on top of years of bankruptcy theater and courtroom bruises around J&J’s effort to contain tens of thousands of talc-related cancer claims. The broader issue hasn’t changed: every new development keeps the litigation pile hot, expensive, and very much not over.
Big picture
For J&J, this isn’t a balance-sheet earthquake by itself. But it’s the kind of credibility hit that can make settlement talks uglier and defense strategy shakier. In other words: less “case closed,” more “the sequel nobody asked for.”